CalciMedica Inc CALC

Healthcare

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

NDAQ:CALC - Post by User

CalciMedica Inc

<< Previous

Bullboard Posts

Next >>

Post by alphaflighton Oct 11, 2022 8:13pm

214 Views

Post# 35018520

Graycliff Exploration Reports More High-Grade From Phase 4

Graycliff Exploration Reports Further High-Grade Gold Assay Results in Phase 4 Drilling at Shakespeare Project, Ontario

Expands the Width and Breadth of the Mineralized Zone

TORONTO, ON – October 11, 2022 - Graycliff Exploration Limited (the “Company” or “Graycliff”) (CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0) is pleased to release the next batch of assay results from the Phase Four drilling program at the Shakespeare Gold Project located on the Canadian Shield near Sudbury, Ontario. Phase Four drilling focused on testing the boundaries of the mineralized zone, both along strike and at depth.

Drill Hole J-52 intersected 14.39 grams per tonne of gold (“g/t Au”) over 3.0 metres (“m”), including 41.00 g/t Au over 1.0 m. Additionally, J-53 intersected 5.35 g/t Au over 5.0 m, including 21.40 g/t Au over 1.0 m. Significant intervals for Holes J-52 to J-53 are detailed below.

James Macintosh, Graycliff’s President and CEO, stated: “Drill Hole J-52 was drilled to the northeast and expanded the width and breadth of the mineralization zone. Hole J-53 intersected three anomalous intervals at depth of over 150 m from surface within a 25 m section of the hole. Given the intersection of high grades over the strike as well as depth drilled to date, we feel it’s time for us to initiate preliminary metallurgical sample test work. Our team will complete one or several drill holes of large diameter to collect material for the anticipated work. This should become an important step in moving the Shakespeare Project forward.”

Figure 1 - Holes J-52 to J-53 Location and Cross Section

Qualified Person

Bruce Durham, P.Geo., is a Qualified Person, as that term is defined by Canadian regulatory guidelines under NI 43-101, and has read and approved the technical information contained in this press release.

About Graycliff Exploration Limited

Graycliff Exploration is a mineral exploration company focused on its 1,025 hectares of prospective ground, located roughly 80 kilometres west of Sudbury on the prolific Canadian Shield. The Company's Shakespeare Project consists of one crown patented lease, two crown leases and 40 claims on a property associated with the historic Shakespeare Gold Mine, which operated from 1903 to 1907. Graycliff’s Baldwin Project is adjacent to the east and is comprised of 68 claims covering 1,500 hectares. This brings our total land package in the area to 2,525 hectares.

QA/QC Protocol: https://graycliffexploration.com/wp-content/uploads/2021/06/graycliffexploration-qa-qc-protocols-june-2021.pdf